РОЛЬ ЛАТЕНТНОГО ВОСПАЛЕНИЯ В ПАТОГЕНЕЗЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
Аннотация
Рассматриваются вопросы участия воспалительных процессов в генезе фибрилляции предсердий, оценивается информативность таких маркеров воспаления как С-реактивный белок, интерлейкин, фактор некроза опухоли в качестве предикторов течения фибрилляции предсердий.
Об авторах
К. Г. Адамян
Институт кардиологии, Национальный институт здравоохранения, Ереван, Армения
Россия
Россия
С. В. Григорян
Институт кардиологии, Национальный институт здравоохранения, Ереван, Армения
Россия
Россия
Л. Г. Азарапетян
Институт кардиологии, Национальный институт здравоохранения, Ереван, Армения
Россия
Россия
Список литературы
1. Аникин В.В., Калинкин М.Н., Вороная Ю.Л. Показатели иммунной системы у больных с нарушениями ритма сердца //Российский кардиологический журнал, 2001, 3, 22-27.
2. Беленков Ю.Н., Агеев Ф.Т., Мареев В.Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого заболевания? // «Сердечная недостаточность», 2000, 1, 4, 1-8.
3. Вахляев В. Д., Недоступ А.В., Царегородцев Д. А., Мазинг М.Ю. Роль гуморальных факторов в патогенезе аритмий сердца // Росс. мед. журнал, 2000, 2, 54-56.
4. Волков В.И., Саламех Х.Н., Серик С.А. Про- и противовоспалительные цитокины при сердечной недостаточности В сб: Научные труды Харьк. Гос. мед. института, 2007, 2, 23-28.
5. Гуревич М.А. Практические аспекты этиологии, систематизации и лечения мерцательной аритмии // Кардиология, 2001, 7, 14-18.
6. Зотова И.В., Затейщиков Д.А., Сидоренко Б.А. Предикторы внутрисердечного тромбоза у больных с мерцательной аритмей : факторы гемостаза, маркеры воспаления и генетические факторы // Кардиология, 2007, 11, 46-54.
7. Клиническая иммунология. / Под ред. Караулов А.В.- М., 1999, 600 с.
8. Кушаковский М. С. Аритмии сердца. Руководство для врачей, СПб.: ИКФ «Фолиант»» 2004, 672 с.
9. Литвицкий П.Ф., Войнов В.А. Патофизиология. Часть 1. М., 1992, с. 60-72.
10. Насонов Е.Л. Современные иммунологические концепции в кардиологии // Тер. арх. 1986, 10, 7-14.
11. Насонов Е.Л. Маркеры воспаления и атеросклероз: значение С-реактивного белка // Кардиология, 1992, 2, 81-85.
12. Насонов Е.Л., Панюкова Е.В., Александрова Е.Н. С-реактивный белок - маркер воспаления при атеросклерозе (новые данные) // Кардиология, 2002, 7, 53-62.
13. Насонов Е.Л., Самсонов М.Ю, Беленков Ю.Н. Иммунопатология застойной сердечной недостаточности: роль цитокинов // Кардиология, 1999, 3, 66-73.
14. Насонов Е.Л., Самсонов М.Ю. Новые аспекты патогенеза сердечной недостаточности: роль фактора некроза опухоли // Мед. русс. журнал, 2000, 1, 4, 22-36.
15. Озова Е.М., Киякбаев Г.К., Кабалава Ж.Д. Воспаление и хроническая сердечная недостаточность. Роль статинов // Кардиология, 2007, 1, 52-62.
16. Ольбинская Л.И., Игнатенко С.Б. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с хронической сердечной недостаточностью // Сердечная недостаточность, 2001, 2, 3, 33-39.
17. Тарасова О.А. Роль маркеров воспаления при фибрилляции предсердий // Врач, 2007, 1 (16), 49-53.
18. Тарасова О.А. С-реактивный протеин и фактор некроза опухолей-альфа при фибрилляции предсердий у пациентов с артериальной гипертонией, их прогностическая значимость // Сибирский медицинский журнал, Томск, 2007, 1(22), 29-34.
19. Тарасова О.А. СРП и ФНО-альфа при фибрилляции предсердий // Актуальные вопросы клинической медицины, Пермь, 2005, 146-150.
20. Фрейдлин И.С. Цитокины и межклеточные контакты в противоинфекционной защите организма В Сб: Труды С-Пб мед. университета 2007, 3, 21-27.
21. Abdelhadi R.H.,Chung M.K.,Wagoner D.R. New hope for the prevention of recurrent atrial fibrillation // Circulation, 1997, 96, 3542-3548.
22. Acevedo M. et al. C-reacrive protein and atrial fibrillation: evidence for the presence of inflammation in the perpetuation of the arrhythmia // Int. J Cardiolog. 2006, 14, 108 (3), 326-331.
23. Agmon Y., Khandheria B., Meissner I. et al. Serum C-reactive protein levels are associated with the presence and severity of atherosclerosis of the thoracic aorta; a population-based transesophageal echocardiographic study // Circulation 2000, 102, II, 43.
24. AndersonJ.L., Maycock C.A., Lappe D. Frequency of elevation of C-reactive protein in atrial fibrillation // Am. J. Cardiol. 2004, 94, 1255-1259.
25. Aviles R.J., Martin D.O., Apperson-Hansen C. et all. Infiammation as a rick factor for atrial fibrillation // Circulation 2003, 108 (24), 3006-3010.
26. Azzawi M., Hasleton P. Tumor necrosis factor alpha and cardiovascular system: its role in cardiac allograft and heart disease // Cardiovasc. Res. 1999, 850-859.
27. Bataile R., Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo // Arthritis Rheum 1992, 35, 982-984.
28. Bazzоni F., Beutier B. Tumor necrosis factor ligant and receptor families // N. Engl. J. Med. 1996, 334, 1717-1725.
29. Biasucci L., Liuzzo G., Grillo R.L. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability // Circulation 1999, 99, 855-860.
30. Biasucci L.M., Vitelli A., Liuzzo G. et al. Elevated levels of interleukin-6 in unstable angina // Circulation, 1996, 94, 5, 874-877.
31. Biasucci LM. CDC/AHA Workshop on markers of inflammation and cardiovascular disease; application to clinical and public health practice; clinical use of inflammatory markers in patients with cardiovascular diseases; a background paper // Circulation 2004, 110, 560-567.
32. Boss Ch.J, Anderson R.A. Lip G.Y.H. Is atrial fibrillation an inflammatory disorders? // Eur. Heart J. 2006, 27, 136-149.
33. Boss Ch.J, Lip G.Y.H. Targeting the renin-angiotensin -aldosterone system in atrial fibrillation: from pathology to clinical trials // J. Hum. Hypertens, 2005, 19, 855-859.
34. Boss Ch.J., Lip G.YH. Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers // J. Am. Coll Cardiol 2006, 47, 889-890.
35. Bozkurt B., Kribbs S.B., Clubb F.J. et all. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats // Circulation 1998, 97, 1382-1391.
36. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis // J Am Coll Cardiol 1998, 32(7), 2057-2064.
37. Cheruku K.K., Ghani A., Ahmad F. et al. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary bypass graft surgery // Prev Cardiol, 2004, 7, 13-18.
38. Chloe A. et al. Is atrial fibrillation an inflammatory disease reflected be elevation C-reactive protein? // Suppl to J. of the American College of Cardiology 2003, March, l 41, 6, Suppl. A absrt 1089-17/
39. Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation // Circulation 2001, 104, 2886-2891.
40. Conway D.S.G. et al. Relationship of Interkeukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation // J. of the American College of Cardiology, 2003.
41. Corrado E, Rizzo M, Tantillo R, et all. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study // Stroke 2006, 37, 482-486.
42. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses // BMJ 2000, 22, 321 (7255), 199-204.
43. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation // Amer. Heart J, 2005, 12-14.
44. Dernellis J., Panareotou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implicftion of an inflammatory process in paroxysmal atrial fibrillation // Acta Cardiol, 2001, 56, 375-380.
45. Dernellis J., Panareotou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation // Eur. Heart J, 2004, 25, 1100-1107.
46. Ellinor P.T. et al. C-reactive protein in lone atrial fibrillation // Am J Cardiol 2006, 1, 98 (7), 991-992.
47. Engelmann M.D., Ogard C.G., Niemann L et al. Increased levels of multiple markers of inflammation in patients with persistent atrial fibrillation // Scan. Cardiovasc. J. 2005, 39, 36.
48. Engelmann M.D., Svedsen J.H The emerging role of inflammation in atrial fibrillation and the potential of antiinflammatory intervention: reply // Eur.Heart J., 2005, 26 (20), 2208-2209.
49. Engelmann M.D.M., Svedsen J.H. Inflammation in the genesis of atrial fibrillation // Eur. Heart J. 2005, 20(26), 2083-2092.
50. Falk R.H. Atrial Fibrillation // NEJM 2001, 344, 14, 1067-1078.
51. Ford E.S., Giles W.H. Serum C-reactive protein and self- reported stroke. Findings from the Third National Health and Nutrition Examination Survey // Arteriocler Thromb Vasс Biol 2000; 20: 1052-1056.
52. Gabay C., Kushnewer I. Acute-phase proteins and other systemic responses to inflammation // N Engl J Med 1999, 340, 448-454.
53. Haverkate F., Thompson S.G., Pyke S.D.M. et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina // Lancet 1997, 349, 462-466.
54. Hernandez A. C-reactive protein and atrial fibrillation. An old marker looking for new target // Rev. Esp. Cardiol. 2006, 59, 94-98.
55. Issac T.T., Dokanish H., Lakkis N.M. Amer. J. Cardiol. 2007, 11, 443-445
56. Kallergis E.M. et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation // Heart rhythm disorders and pacemakers, 2007, 2, 443-446.
57. Koening W., Sund M., Frohlich M. et al. C-reactive protein, a sensitive marker of inflammation, predict future risk of coronary heart disease in initially healthy middle-aged men. Results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort study, 1984 to 1992 // Circulation 1999, 99, 237-242.
58. Lagrand W.K., Visser C.A., Hermens W.T et al. C- reactive protein as cardiovascular risk factor: more than an epiphenomenona // Circulation 1999, 1000, 96-102.
59. Lee KWJ, Hill JS, Walley KR et al. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort // CMAJ 2006, 174, 461-466.
60. Lindahl B, Toss H, Siegbahn A et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease // N Engl J Med 2000, 343 (16), 1139-1147.
61. Loricchio M.L., Cianfrocca C., Pasceri V et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardiovertion // Am. J. Cardiol. 2007, 99, 1421-1424.
62. Mann D.J., Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines // Chest 1994, 105, 897-904.
63. Martins TB, Anderson JL, Muhlestein JB et all. Risk factor analysis of plasma cytokines in patient with coronary artery disease by a multiplexed fluorescent immunoassay // Am J Clin Pathol 2006, 125, 906-913.
64. Mendall M.A., Strachman D.P., Butland B.K. et al. C-reactive protein: relation to total mortality, cardiovascular risk factors in man // Eur Heart J 2000, 21,1584-1590.
65. Muhlestein JB, Anderson JL, Carlquist JF et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease // Circulation, 2000, 102, 1755-1760.
66. Muller-Werdan U, Werdan K. Immune modulation by catecholamines - a potential mechanism of cytokine release in Heart failure // Herz 2000, 25, 3, 1838-1842.
67. Nissen S.E ,Tuzcu E.M.,Schoenhagen P et a.l Effect of intensive compared with moderate lipid-loowering therapy on progression of coronary athresclerosis: a randomized controlled trial // JAMA, 2004, 291, 1071-1080.
68. Ockene L.S., Mathews C.D., Rifai N. et all. Validity and classification accuracy of serial nigh-sensitive C-reac tive protein measurements in healthy adults // Clin Chem 2001, 47, 444-450.
69. Pearson TA, Mensah GA, Alexander RW et all. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and American Heart Association // Circulation 2003, 107, 499-551.
70. Pepys M.B, Hirschfield G.M. C-reactive protein: a critical update // J.Clin. Invest 2003, 111, 1805-1812.
71. Psichary S.N. et al. Relation of elevated C-reactive protein and IL-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation // Am.J.Cardiol. 2005, 95, 764-767.
72. Rader D. J. Inflammatory markers of coronary risk // N Engl J Med 2000, 343, 1179-1182.
73. Rauchhaus M et all Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure // J. Am. Coll. Cardiol. 2003, 42, 1933-1940.
74. Rauchhaus M, Doeher W, Francis DP et al. Plasma cytokine parameters and mortality in patients with chronic heart failure // Circulation 2000, 102, 3060-3067.
75. Ridker P., Hennekens C., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women // N Engl J Med 2000, 836-843.
76. Ridker P.M. High-sensitive C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease // Circulation 2001, 103, 1813-1821.
77. Ridker P.M., Buring J. E., Shin J et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparentiy healthy women // Circulation 1998, 98, 731-733.
78. Ridker P.M., Cushman M., Stampfer M.J. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men // N Engl J Med 1997, 336, 973-979.
79. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction // Circulation, 1998, 97, 2007-2011.
80. Ridker PM, Rifai N. Pfeffer MA et all. Inflammation, Pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels // Circulation 1998, 98, 839-844.
81. Rifai N., Tracy R. P., Ridker P. M. Clinical efficacy ofan automated highsensitivity C-reactive protein assay // Clin Chem 1999; 45: 2136-2141.
82. Roberts W.L., Moulton L., Law T. C. et al. Evaluation of nine automated high sensitive C-reactive protein methods; implications for clinical and epidemiological applications // Clin Chem 2000, 47, 418-423.
83. Roberts W.L., Sedrick R., Moulton L. et al. Evaluation of four automated high-sensitive C-reactive protein methods; implications for clinical and epidemiological applications // Clin Chem 2000, 46, 461-468.
84. Roivanen M., Viik-Kajander M., Palouso T. et al. Infections, inflammation, and the risk of coronary heart disease // Circulation 2000, 10, 252-257.
85. Sanchez P.L. et al. Do baseline C-reactive protein lev els predict the new - onset of atrial fibrillation in hftients with acute coronary syndrome? // Europ. Heart J. 2003. Suppl August - September 24, abstr 509.
86. Sata N., Hamada N. et al. C-Reactive Protein and atrial fibrillation. Is inflamation a conssequence or a cause of atrial fibrillation? // Jpn Heart J 2004, 45, 3, 441-445.
87. Schonbek U, Libby P. Inflammation, Immunity, and HMG-CjA Reductase Inhibitors: Statins as Antiinflammatory Agents? // Ciculation 2004, 109, 18-26.
88. Serrano C.V., Ramires J.A.F., Venturinelli M. et al. Coronary angioplasty results in leukocytes and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty // J Am Coll Cardiol 1997, 29, 1276-1283.
89. Sideris A.N., Letsas K. Inflammation and Atrial Fibrillation // Hospital Chronicles 2006, Suppl. 128-134.
90. Steel D.M., Alexander A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid protein A. // Immunol Today 1994, 74, 80-87.
91. Stranberg T.E., Tilvis R.S. C-reactive protein. Cardiovascular risk factors, and mortality in the prospective study in the elderly // Arterioscl. Thromb. Vasc. Biol 2000, 20, 1057-1060.
92. Szodoray P, Timar O, et all. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines - immunological alterations in acute coronary syndrome and stable coronary artery disease // Scand J Immunol 2006, 64, 336-344.
93. Toss H., Lindahl B., Siegbahn A. et al. For the FRISC Study Group. Prognostic influence of fibrinogen and C-reactive protein levels in unstable coronary artery disease // Circulation 1997, 96, 4204-4210.
94. Tracy R.P. Inflammation in cardiovascular disease. Cart, Horse, or Both. // Circulation 1998, 97, 2000-2002.
95. Tracy R.P. Inflammation markers and coronary heart disease. // Curr Opin Lipidol 1999, 10, 435-441.
96. Vanderheyden M, Kersschot E, Paulus W. Pro-inflammatory cytokines and endothelium-depent vasodilatation in the forearm // Eur.Heart J. 1998, 19, 747-752.
97. Vigushi D.M., Pepys M., Hawkins P.N. Metabolic and scintigraphic studies of radiodinated human C-reactive protein in health and disease // J Clin Invest 1993, 91, 1351-1357.
98. Watanabe T., Takeishi Y., Hirono O. et al. C-reactive protein elevation predicts the occurrence of atrial structual remodeling in patients with paroxysmal atrial fibrillation // Heart Vessels 2005, 20, 2, 45-49.
99. Wazni O., Martin D.O., Marrouche N.F. et al. Creacrive protein concentration and reccurence of atrial fibrillation after electrical cardioversion // Heart 2005, 91, 1303-1305.
100. Wei C.M., Lerman A., Rodeheffer R.J. et al. Endothelin in human congestive heart failure // Circulation 1994, 89, 1580-1586.
101. Woods A., Brull D. J., Humphries S. E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6 // Eur Heart J 2000, 21, 1574-1583.
102. Zhang M., Tracey K.L. Tumor necrosis factor. In : Thompson A.W. The cytokine handbook? 3-rd ed. New York, Academic press, 1998, 515-548.
Рецензия
Для цитирования:
Адамян К.Г., Григорян С.В., Азарапетян Л.Г. РОЛЬ ЛАТЕНТНОГО ВОСПАЛЕНИЯ В ПАТОГЕНЕЗЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Вестник аритмологии. 2008;54(54):34-41.
For citation:
Adamyan K.G., Grigoryan S.V., Azarapetyan L.G. ROLE OF LATENT INFLAMMATION IN PATHOGENY OF ATRIAL FIBRILLATION. Journal of Arrhythmology. 2008;54(54):34-41. (In Russ.)
Просмотров:
121
Послать статью по эл. почте 